Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03456700 · ClinicalTrials.gov registry record · Phase 2
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT03456700: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT03456700 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03456700, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This phase II trial studies how well auranofin and sirolimus work in treating participants with ovarian cancer. Immunosuppressive therapy, such as auranofin and sirolimus, is used to decrease the body?s immune response and may increase blood cell count.
Interventions
- DRUG Sirolimus
- OTHER Laboratory Biomarker Analysis
- DRUG Auranofin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-03-30 |
| Est. Completion | 2019-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03456700
The ClinicalTrials.gov registry entry for NCT03456700 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sirolimus is the first listed.
NCT03456700 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03456700 about?
NCT03456700 is a clinical study titled "Auranofin and Sirolimus in Treating Participants With Ovarian Cancer". This phase II trial studies how well auranofin and sirolimus work in treating participants with ovarian cancer. Immunosuppressive therapy, such as auranofin and sirolimus, is used to decrease the body?s immune response and may increase blood cell count.
What is the current status of trial NCT03456700?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2018-03-30. Estimated completion is 2019-07-31.
What interventions are being tested in trial NCT03456700?
The interventions under investigation include: Sirolimus (DRUG), Laboratory Biomarker Analysis (OTHER), Auranofin (DRUG).
Who is sponsoring clinical trial NCT03456700?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.